213 related articles for article (PubMed ID: 15609329)
1. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
[TBL] [Abstract][Full Text] [Related]
3. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
4. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
Evans M; Borysiewicz LK; Evans AS; Rowe M; Jones M; Gileadi U; Cerundolo V; Man S
J Immunol; 2001 Nov; 167(9):5420-8. PubMed ID: 11673561
[TBL] [Abstract][Full Text] [Related]
5. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
[TBL] [Abstract][Full Text] [Related]
6. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
7. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones.
Schreurs MW; Scholten KB; Kueter EW; Ruizendaal JJ; Meijer CJ; Hooijberg E
J Immunol; 2003 Sep; 171(6):2912-21. PubMed ID: 12960314
[TBL] [Abstract][Full Text] [Related]
8. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
10. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
[TBL] [Abstract][Full Text] [Related]
11. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
12. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
14. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
15. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
[TBL] [Abstract][Full Text] [Related]
17. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
[TBL] [Abstract][Full Text] [Related]
18. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
19. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
Ressing ME; de Jong JH; Brandt RM; Drijfhout JW; Benckhuijsen WE; Schreuder GM; Offringa R; Kast WM; Melief CJ
Eur J Immunol; 1999 Apr; 29(4):1292-303. PubMed ID: 10229097
[TBL] [Abstract][Full Text] [Related]
20. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
Bauer M; Wagner H; Lipford GB
Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
